Abstract | Purpose: To explore the effect of erdosteine on COPD exacerbations, health-related quality of life (HRQoL), and subjectively assessed COPD severity. Patients and methods: This post-hoc analysis of the RESTORE study included participants with COPD and spirometrically moderate ( GOLD 2; post- bronchodilator forced expiratory volume in 1 second [FEV1] 50‒79% predicted; n = 254), or severe airflow limitation ( GOLD 3; post- bronchodilator FEV1 30‒49% predicted; n = 191) who received erdosteine 300 mg twice daily or placebo added to usual maintenance therapy for 12 months. Antibiotic and oral corticosteroid use was determined together with patient-reported HRQoL (St George's Respiratory Questionnaire, SGRQ). Patient and physician subjective COPD severity scores (scale 0‒4) were rated at baseline, 6 and 12 months. Data were analyzed using descriptive statistics for exacerbation severity, COPD severity, and treatment group. Comparisons between treatment groups used Student's t-tests or ANCOVA as appropriate. Results: Among GOLD 2 patients, 43 of 126 erdosteine-treated patients exacerbated (7 moderate-to-severe exacerbations), compared to 62 of 128 placebo-treated patients (14 moderate-to-severe exacerbations). Among those with moderate-to-severe exacerbations, erdosteine-treated patients had a shorter mean duration of corticosteroid treatment (11.4 days vs 13.3 days for placebo, P = 0.043), and fewer patients required antibiotic treatment with/without oral corticosteroids (71.4% vs 85.8% for placebo, P < 0.001). Erdosteine-treated GOLD 2 patients who exacerbated showed significant improvements from baseline in SGRQ total scores and subjective disease severity scores (patient- and physician-rated), compared with placebo-treated patients regardless of exacerbation severity. Among GOLD 3 patients, there were no significant differences between treatment groups on any of these measures. Conclusion:
|
Authors | Peter M A Calverley, Alberto Papi, Clive Page, Paola Rogliani, Roberto W Dal Negro, Mario Cazzola, Arrigo F Cicero, Jadwiga A Wedzicha |
Journal | International journal of chronic obstructive pulmonary disease
(Int J Chron Obstruct Pulmon Dis)
Vol. 17
Pg. 1909-1920
( 2022)
ISSN: 1178-2005 [Electronic] New Zealand |
PMID | 36034589
(Publication Type: Journal Article)
|
Copyright | © 2022 Calverley et al. |
Chemical References |
- Adrenal Cortex Hormones
- Anti-Bacterial Agents
- Bronchodilator Agents
- Thioglycolates
- Thiophenes
- erdosteine
|
Topics |
- Adrenal Cortex Hormones
- Anti-Bacterial Agents
- Bronchodilator Agents
- Forced Expiratory Volume
- Humans
- Pulmonary Disease, Chronic Obstructive
- Quality of Life
- Thioglycolates
- Thiophenes
|